These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27439631)

  • 21. Febrile neutropenia in haematological malignancies.
    Sharma A; Lokeshwar N
    J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
    Cherif H; Johansson E; Björkholm M; Kalin M
    Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
    Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
    Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective audit of treatment of paediatric febrile neutropenia in Australasia.
    Chamberlain JD; Smibert E; Skeen J; Alvaro F
    J Paediatr Child Health; 2005 Nov; 41(11):598-603. PubMed ID: 16398846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period.
    Parodi RL; Lagrutta M; Tortolo M; Navall E; Rodríguez MS; Sasia GF; De Candia LF; Gruvman MA; Bottasso O; Greca AA
    PLoS One; 2019; 14(10):e0224299. PubMed ID: 31671108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological malignancies at Sultan Qaboos University Hospital, Oman.
    Al Balushi KA; Balkhair A; Ali BH; Al Rawas N
    J Infect Public Health; 2013 Jun; 6(3):216-21. PubMed ID: 23668467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of ¹⁸F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia.
    Gafter-Gvili A; Paul M; Bernstine H; Vidal L; Ram R; Raanani P; Yeshurun M; Tadmor B; Leibovici L; Shpilberg O; Groshar D
    Leuk Res; 2013 Sep; 37(9):1057-62. PubMed ID: 23849986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
    Kaya S; Köksal I; Menteşe A; Sönmez M; Sümer A; Yıldırım SS; Yılmaz G
    Int J Infect Dis; 2013 Nov; 17(11):e1056-9. PubMed ID: 23742830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.
    Sato T; Kobayashi R; Yasuda K; Kaneda M; Iguchi A; Kobayashi K
    Pediatr Blood Cancer; 2008 Dec; 51(6):774-7. PubMed ID: 18661495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.
    Girmenia C; Russo E; Carmosino I; Breccia M; Dragoni F; Latagliata R; Mecarocci S; Morano SG; Stefanizzi C; Alimena G
    Ann Hematol; 2007 Apr; 86(4):263-70. PubMed ID: 17225113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
    Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
    Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
    Klastersky J; Paesmans M; Rubenstein EB; Boyer M; Elting L; Feld R; Gallagher J; Herrstedt J; Rapoport B; Rolston K; Talcott J
    J Clin Oncol; 2000 Aug; 18(16):3038-51. PubMed ID: 10944139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort study.
    Offidani M; Corvatta L; Malerba L; Marconi M; Bichisecchi E; Cecchini S; Manso E; Principi T; Gasparini S; Leoni P
    Cancer; 2004 Aug; 101(3):567-77. PubMed ID: 15274070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucocutaneous findings in febrile neutropenic children with acute leukemias.
    Wananukul S; Nuchprayoon I; Siripanich H
    J Med Assoc Thai; 2005 Jun; 88(6):817-23. PubMed ID: 16083222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
    Karthaus M; Südhoff T; Fenchel K; Egerer G; Kämpfe D; Ritter J; Franke A; Heil G; Peters G; Jürgens H
    Wien Med Wochenschr; 1998; 148(21):481-7. PubMed ID: 10048176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia.
    Koivula I; Hämäläinen S; Jantunen E; Pulkki K; Kuittinen T; Nousiainen T; Juutilainen A
    Scand J Infect Dis; 2011 Jul; 43(6-7):471-8. PubMed ID: 21299364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
    Ritchie S; Palmer S; Ellis-Pegler R
    Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chemotherapy-induced febrile neutropenia: about 200 episodes. Clinical, microbiological and therapeutic characteristics].
    Gharbi O; Ben Hadj Hassen S; Kaabia N; Limam S; Hadj Amor M; Ben Fatma L; Landolsi A; Hochlef M; Letaief A; Boukadida J; Ben Ahmed S
    Pathol Biol (Paris); 2008 May; 56(3):154-7. PubMed ID: 18178025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer.
    Paganini HR; Aguirre C; Puppa G; Garbini C; Ruiz Guiñazú J; Ensinck G; Vrátnica C; Flynn L; Iacono M; Zubizarreta P;
    Cancer; 2007 Jun; 109(12):2572-9. PubMed ID: 17492687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.